Skip to content
buyModerate cluster of 4

SR One Capital Fund I Aggregator LP bought $7.6M of DSGN

owner at Design Therapeutics, Inc.. 900,000 shares at an average of $8.42, traded Dec 16, 2022, filed Dec 20, 2022.

Conviction score
58
Value
$7.6M
900,000 shares
Holdings after
6,526,476
+16% from before
From 52-week low
+11%
low $7.86, close $8.76
From 52-week high
-66%
high $25.57, as of Dec 16, 2022

Score components

  • Role
    10% owner
    +12
  • Trade size
    $7.6M at market
    +25
  • Relative to holdings
    Holdings up 16%
    +3
  • Price context
    66% below the 52-week high
    +8
  • Cluster
    4 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

DSGNOct 12, 2026 · close 10.91
Since filing Dec 20, 2022: +35.4%SPY +114.3% · excess -79.0%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001209191-22-062226, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 16, 2022POpen-market purchase
Common Stock
+500,000$8.28$4.1M6,126,476Dec 20, 2022
Dec 19, 2022POpen-market purchase
Common Stock
+360,000$8.63$3.1M6,486,476Dec 20, 2022
Dec 20, 2022POpen-market purchase
Common Stock
+40,000$8.14$325k6,526,476Dec 20, 2022

Related signals

Other insiders at Design Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
45Moderate
DSGNsell
Design Therapeutics, Inc.
Arsani William
director
$3.0M
562,627 shares
-19%
20Weak
DSGNsell
Design Therapeutics, Inc.
Deepa Prasad
director
$24k
3,806 shares
-16%
60Notable
DSGNsell
Design Therapeutics, Inc.
Arsani William
director
$3.5M
814,874 shares
-100%
39Weak
DSGNbuy 2
Design Therapeutics, Inc.
Heather A. Berger
director
$4,866
1,300 shares
-
49Moderate
DSGNbuy 2
Design Therapeutics, Inc.
John P. Schmid
director
$100k
26,965 shares
-
69Notable
DSGNbuy 4
Design Therapeutics, Inc.
Joao Siffert MD
President and CEO
$63k
7,450 shares
+6%
66Notable
DSGNbuy 4
Design Therapeutics, Inc.
Simeon George
director, owner
$7.6M
900,000 shares
+16%
61Notable
DSGNbuy 4
Design Therapeutics, Inc.
Rodney W Lappe
director
$119k
15,000 shares
+15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SR One Capital Fund I Aggregator LP bought $7.6M of DSGN | InsiderTell